This paper describes work to develop a novel human antibody nasal spray as a prophylactic treatment against SARS-CoV-2. Formulations were developed at two protein concentrations and assessed for delivery using an Aptar VP3 nasal spray pump. Both formulations were shown to be suitable for nasal delivery in terms of pH, osmolality, and delivered droplet size; no evidence of protein agglomeration was observed as a result of spraying. Further studies are planned to investigate the stability of the developed products and to establish pharmacokinetics and pharmacodynamics.
